Check for updates





Blood 142 (2023) 6472-6473

The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

637.MYELODYSPLASTIC SYNDROMES - CLINICAL AND EPIDEMIOLOGICAL

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Roger M. Lyons, MD¹, Brandon Foster², Adrian Jewett², Liu Liu², Rohini Sen³, Cat N. Bui, PharmD, PhD³, Rajesh Kamalakar, MS³, Jalaja Potluri³

¹Department of Hematology, Texas Oncology and US Oncology Research, San Antonio, TX

²Lumanity, Bethesda, MD

³AbbVie Inc., North Chicago, IL

Background : Patients with myelodysplastic syndromes (MDS) can experience fatigue, infection, anemia, bruising, and bleeding. Fatigue and physical functioning (PF) are often the most adversely impacted areas of patient health-related quality of life. The objective of this study was to generate quantitative evidence to determine whether the PF score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Fatigue score from the Patient-Reported Outcome Measurement Information System - Fatigue Short Form 7a (PROMIS SF 7a) measures are suitable candidates for developing patient-reported endpoints for clinical trials in treatment-naïve patients with higher-risk MDS (HR-MDS). We also aimed to derive definitions for meaningful change for both PF and Fatigue scores to aid in interpretation of efficacy analyses using these scores.

Methods : This analysis used aggregate data from the Phase 3 M15-954 study (NCT04401748), which is an ongoing, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve adult patients with HR-MDS. The EORTC QLQ-C30 and the PROMIS SF 7a questionnaires were administered on the first day of each 28-day cycle for the first 7 cycles and every 3 cycles thereafter, and at the treatment-completion visit. For both measures, the analyses evaluated item characteristics at baseline, whether the hypothesized structure was consistent with the scoring algorithms implemented in the trial, and the reliability and validity of scores; subsequently, definitions for meaningful improvement or deterioration were determined. Anchor-based analyses were used to generate definitions for meaningful deterioration or improvement from baseline to Cycle 4 Day 1 for EORTC QLQ-C30 PF domain, and Cycle 7 Day 1 for PROMIS SF 7a. Construct-aligned anchors were used for these analyses, with a change in Patient Global Impression of Severity (PGIS) - Physical Activities and in Patient Global Impression of Change (PGIC) - Physical Activities used as the anchor for the analyses of the EORTC QLQ-C30 PF scores and PGIS-Fatigue and PGIC-Fatigue used for the analyses of the PROMIS SF 7a scores.

Results : Approximately 500 treatment-naïve higher-risk patients with MDS enrolled in the study were included in this analysis. Both EORTC QLQ-C30 PF and PROMIS SF 7a measures demonstrated adequate reliability and validity; both measures exceeded the cut-off for acceptable internal consistency reliability, test re-test reliability, and convergent validity with co-validators (**Table 1**). The definition for deterioration for the EORTC QLQ-C30 PF domain was -13.33 (rounded to the nearest possible incremental change score), which was corroborated with the PGIC-Physical Activities (**Table 2**). The correlation between the EORTC QLQ-C30 PF domain and PGIS-Physical Activities scores was -0.43, and the correlation between the EORTC QLQ-C30 PF domain and PGIC-Physical Activities scores was -0.34, indicating that these measures were sufficient to be used as anchors. For PROMIS SF 7a, the definition for deterioration and improvement was 3.90 and -3.50, respectively. Both results were also corroborated with the PGIC-Fatigue. The correlation between the PROMIS SF 7a and PGIS-Fatigue scores was 0.58, and the correlation between the PROMIS SF 7a and PGIC-Fatigue scores was 0.38, indicating that these measures were sufficient to be used as anchors.

Conclusions : The psychometric evaluation of EORTC QLQ-C30 PF and PROMIS SF 7a Fatigue scores from M15-954 study's blinded data provides sufficient evidence of test re-test reliability, construct validity, responsiveness, and score interpretability and supports their use as endpoints for clinical trials in treatment-naïve HR-MDS patients for regulatory decision-making.

ONLINE PUBLICATION ONLY

Session 637

Disclosures Lyons: Incyte Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Exact Sciences: Research Funding; Pfizer: Research Funding; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas Pharma: Research Funding; Texas Oncology: Current holder of stock options in a privately-held company; McKesson: Other: Leadership; Lessen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Foster: Lumanity: Current Employment. Jewett: Lumanity: Current Employment. Liu: Lumanity: Current Employment. Sen: AbbVie Inc: Current Employment, Current holder of stock options in a privately-held company. Bui: AbbVie Inc: Current Employment, Current holder of stock options in a privately-held company. Kamalakar: AbbVie Inc: Current Employment, Current holder of stock options in a privately-held company. Potluri: AbbVie: Current Employment, Current holder of stock options in a privately-held company.

Paychemetric component	Baccese orderion	Summary of EORTC 01.0-C30 Physical Functioning Daniels	Summary of the PROBELSE of all & Feligoe 7a meadle
Washgiess	Norie, and trades reported	 Extended advanced post IB. Massingness rates are low throughout the study. 	 Dubaterial patient dropout post D. Municipates lates are too throughout the shall.
Response distributions	None edimates reported	 Extreme floor effect alternation ments at ID. 	 Extreme from effect almentant in term 2, 2, and 4 at 81.
Descriptive summary of scenes	Nore, editates reported	 Patients were high on physical functioning 	 Patterna have moderate levels of folgue Net access level frame or uniting affects
Interters associations	8.30 + jpt = 0.90	- Consistons while expected range	 Constations within aspected range and direction for terms 1-d; aberrant significations attoened with next 1
Assessment of structure	Acceptable model 18	 Acceptable model fit 	 Acceptable model 8
Internal consistency	10w1+376	 sr20kadurE# 	 iii = 0.70 and us = 0.87
Test retest relability	60(A 1)+878	Bill = 100,A 11 = 0.08 Base including patients using Date through patients using	E FD +1 (CLA, 1) + 1 78 Statise (no change) patients using PDD F dataset
Consequent satisfy	Init a 2.31 and altering the segmented directory	 Ad consistence along 0.31 and 0.54 Appendix direction 	All containing above 3.31 proto the
Kinsen groups validity	Manifest unitaring of animage statem across strate-for POID Physical Activities (SLG-CN) or the POID Paragoe and IPOID A becam (PROMS ST 415 Congoer To) and IPOID A becam program	- Manatania anderlog alsoaried	Hastatic orderry alastast
Norman desclutive change (NDC) and support/venana to change	HEC More extension reported Programs were to the pro- Dipolitized strange from Bi. Nore, frequency, and propert according Severated	MDC + 15.95 to 24.35 years Day 10.15.95 age/facety detensated betweet B, and Cycle 4 Day 1	BCC + 5.01 to 3.54 permit. Only 15 D42Ni experiences between 16 and Cycle 7 Day 1 Only 31 D42Ni experiences between 18, and Cycle 7 Day 1 between 18, and Cycle 7 Day 1
lactor based estimates is assess neutrophi ditensistics	Description accornersion actions actions there are a series and actions there are a series and actions a	- Maaringful dharge = 12.32 ports	-1.50 parts for imposence and 1.80 parts for anti-strategic line (5, and 5, and 5, and 5, and 5, and 5, and 1,

C30 Physical Functioning Domain or meaningful change from baseline of the PROMIS SF v1.0-Fatigue

Anchor group		Median	Mean (SD)
-2	8	13.33	14.17 (14.00)
-1	38	10.00	8.42 (15.63)
0	101	0.00	0.46 (13.67)
1	36	-6.67	-10.00 (14.12)
2	12	~6,67	-9.44 (16.93)
3	2	-23.33	-23.33 (4.71)
4	1	-13.33	-13.33 (NA)
Meaningful deterioration of th Activities ratings at Cycle 4 D	e EORTC QLQ-C30 Physic ay 1	al Functioning Domain str	atified PGIC-Physical
Anchor group	8	Median	Mean (SD)
Much better	42	6.67	8,73 (13.29)
A little better	71	0.00	4.41 (17.24)
No change	59	0.00	-2.60 (16.56)
A little worse	23	-6.67	-8.99 (21,24)
Much worse	3	-13.33	-13.33 (6.67)
Meaningful change of the PRO	OMIS SF v1.0-Fatigue 7a st	ratified by the change in P	GIS-Fatigue
Anchor group		Median	Mean (SD)
-3	1	-27.20	=27.20 (NA)
-2	7	-8.30	-8.06 (3.44)
-1	39	-3.50	-4.50 (6.44)
0	67	0.00	-1.32 (7.16)
1	26	3.90	4.00 (6.62)
2	2	12.70	12.70 (5.80)
3	1	37.90	37.90 (NA)
Meaningful change of the PRO	MIS SF v1.0-Fatigue 7a st	ratified by PGIC-Fatigue ra	tings at Cycle 7 Day 1
Anchor group		Median	Mean (SD)
Much better	44	~6.05	~6.04 (7.17)
A little better	39	-1.40	-1.18 (7.34)
No change	38	0.00	0.39 (6.68)
A limite months	12	2.50	3 23 (10 02)

change in PGIS-Physical Activities was -0.43.

Spearman correlation between the change in EORTC QLQ-C30 Physical Functioning Domain and PGIC-Physical Activities ratings was –0.34. Spearman correlation between the change in PROMIS SF v1.0-Fatigue 7a and the change in PGIS

Fatigue was 0.58.

Spearman correlation between the change in PROMIS Fatigue - Short Form 7a and PGIC-Fatigue ratings was 0.38.

Figure 1

https://doi.org/10.1182/blood-2023-178011